POLTREG SPOLKA AKCYJNA

Their core work

POLTREG is a Polish clinical-stage biotech SME developing a first-in-class regulatory T-cell (TREG) therapy specifically targeting Type 1 Diabetes. Their core work involves sorting and proliferating TREG cells in vitro to produce patient-specific immunotherapy that retrains the immune system to stop attacking insulin-producing beta cells. They progressed from a feasibility and commercialization study (TREGS4DM1) to a full clinical development program (TREG), indicating they are advancing their own proprietary cell therapy product through clinical trials. Their focus is product development and clinical translation, not academic research.

What they specialise in

How they've shifted over time

POLTREG's H2020 trajectory follows a textbook biotech development arc: the 2016 SME Phase 1 project (TREGS4DM1) was a €50,000 feasibility and commercialization study with no detailed keywords, typical of early concept validation. By 2018, they had moved to a €2.5M SME Phase 2 project (TREG) with well-defined clinical vocabulary — diabetes type 1, immunotherapy, T-cells, first-in-class therapy, clinical trials — indicating the product had matured to clinical-stage development. The absence of early-period keywords and the concentration of all technical terms in the recent project suggests this is a single-product company that sharpened its scientific identity as the therapy advanced toward the clinic.

POLTREG is on a product-focused clinical development path — if their TREG trial produced positive results, they are likely seeking licensing partners, out-licensing deals, or Series A investment rather than additional research grants.

How they like to work

POLTREG has acted as sole coordinator in both projects with no recorded consortium partners, which is consistent with the SME Instrument model where a single company drives its own innovation program with external subcontractors rather than academic consortia. This means they are not a typical consortium team-player — they lead their own agenda and contract in expertise as needed. Organizations looking to partner with them would likely engage as service providers (CROs, clinical sites, manufacturing partners) rather than co-PIs.

POLTREG shows zero recorded consortium partners and no cross-country collaborations in the H2020 data, which reflects the solo-applicant nature of the SME Instrument rather than genuine isolation. Their real-world network almost certainly includes clinical trial sites and cell therapy contract manufacturers, but this is not captured in CORDIS data.

What sets them apart

POLTREG occupies a rare niche: a Polish SME with a clinically advanced, disease-specific TREG cell therapy targeting Type 1 Diabetes — an autoimmune condition with no cure and roughly 9 million patients in Europe. Unlike university spin-offs that publish and license, POLTREG appears to be directly developing and owning its therapy as a commercial product. For consortium builders, they bring a proprietary biological platform and clinical trial experience that academic partners cannot replicate.

Highlights from their portfolio

• TREG
  The largest grant (€2.5M, SME Instrument Phase 2) funds a first-in-class clinical trial for a TREG cell therapy in Type 1 Diabetes — a high-stakes, high-value asset if the trial succeeds.
• TREGS4DM1
  The Phase 1 feasibility project that validated the commercial case and unlocked the Phase 2 funding, demonstrating a deliberate, staged EU funding strategy.